You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Chalcogenide Glass Mid-IR Optic Development
SBC: IRRADIANCE GLASS, INC. Topic: AF15AT06ABSTRACT: IRradiance Glass, Inc. proposes a Phase I STTR program in conjunction with the University of Central Florida to demonstrate the feasibility of the design, development, and production of high numerical aperture (NA) cylindrical lenses for use in the mid- to long-wave infrared optical region by extruding chalcogenide glasses into a micro-lens shape (~2mm wide x 2 mm high x 3 mm long) with ...
STTR Phase I 2015 Department of DefenseAir Force -
Prediction and Measurement of the Carbon Build-Up in Film-Cooled Rocket Engines
SBC: SIERRA ENGINEERING, INC. Topic: AF15AT21ABSTRACT: Sierra Engineering Inc. (Sierra) believes that existing chemical kinetic models can be efficiently incorporated into commercial CFD codes to predict the mixing, pyrolysis, soot formation and carbon deposition within film cooled rocket engines. During this Phase I STTR effort we will demonstrate that this analysis capability is practical and that we can generate appropriate model validati ...
STTR Phase I 2015 Department of DefenseAir Force -
Automated assessment of disclosure risk
SBC: SECURBORATION, INC. Topic: AF13AT14ABSTRACT: Information systems continue to progress in terms of collecting, characterizing and assessing information. While this evolution has provided unprecedented intelligence capability to the U.S. and our allies, it has also raised unique challenges in the area of information security and disclosure risks. In particular, the intelligence community (IC) currently lacks the ability to understand ...
STTR Phase II 2015 Department of DefenseAir Force -
Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: 100DESCRIPTION provided by applicant Technology to deliver molecules andquot on demandandquot that bind to targets or catalyze reactions of a technologistandapos s choosing would have enormous commercial value in research manufacturing and medicine Thus this has been a andquot holy grailandquot of molecular science for a half century Even today chemical theory is inadequate to support de ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
RSK3 Anchoring Disruptor Therapy for Heart Failure
SBC: ANCHORED RSK3 INHIBITORS, LLC Topic: NHLBIDESCRIPTION provided by applicant Pathological cardiac remodeling including myocyte hypertrophy and apoptosis and myocardial interstitial fibrosis constitutes a common pathway to heart failure in disease Despite current pharmacologic therapy and other advances that attenuate remodeling mortality due to heart failure remains high New more effective therapeutic options are desperately neede ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: NIAMSDESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Novel piperazine tethered thiazole compounds as antimalarials
SBC: Smart Biomolecules, Inc. Topic: NIAIDDESCRIPTION provided by applicant In spite of all the advances in molecular medicine malaria still afflicts about million people worldwide and half of the world population is at rik The disease causes nearly million deaths each year mostly children Unfortunately the prospects for control of malaria by chemotherapy have been seriously compromised by the emergence of resistance to all av ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.
SBC: MODULATION THERAPEUTICS, INC. Topic: 102DESCRIPTION provided by applicant There are specific high affinity ligands for receptors found on many cancers that have been investigated as imaging probes and we believe that we should try to enhance immunotherapy by using these ligands to deliver immune effectors to the cancer microenvironment Melanoma is among the most immunogenic tumors known and so that disease is an excellent test bed f ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Simple Inexpensive Assay for Five Common HIV Resistance Mutations
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: NIAIDDESCRIPTION provided by applicant Only a few inexpensive drugs can be used in the developing world for the treatment of AIDS Several of these target the HIV reverse transcriptase RT Accordingly patient therapy with these drugs often fails when the gene encoding RT undergoes mutation Thus the WHO recently reported that after months of treatment with anti RT drugs patients most often r ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Neutralization of the Inflammasome After Spinal Cord Injury
SBC: INFLAMACORE LIMITED LIABILITY COMPANY Topic: 105DESCRIPTION provided by applicant Spinal cord injury SCI is a complex and devastating clinical condition mediated by proinflammatory cytokines that produce neuronal loss axonal destruction and demyelination during the secondary injury cascade There are currently no proven therapies targeting posttraumatic inflammation that have been shown to have clinical value We have previously shown th ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health